Pfizer Inc. CEO Net Worth

Last Updated Mar 10, 2025
CEO NameAlbert Bourla
NationalityGreece
Net Worth Estimation$50 million

Albert Bourla's estimated net worth of around $50 million stems from his executive compensation packages at Pfizer Inc., including salary, stock awards, bonuses, and accumulated Pfizer shares. His wealth is also influenced by performance-based incentives, long-term equity grants, and other corporate benefits associated with his CEO role.

Albert Bourla, CEO of Pfizer Inc., has an estimated net worth of $50,000,000, which is exactly halfway (50%) between the healthcare business category's minimum ($10,000,000) and maximum ($90,000,000) CEO net worth estimates. This places him at the median of the estimated CEO wealth range in the healthcare sector.

Business Category: Healthcare

Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD


Albert Bourla Performance in Pfizer Inc.

Albert Bourla, CEO of Pfizer Inc., demonstrates strategic leadership by steering the company through groundbreaking vaccine development and global health challenges. His decisive decision-making accelerated the COVID-19 vaccine approval process, significantly boosting Pfizer's market value and global impact. Under Bourla's leadership, Pfizer achieved record performance, positioning it as a leader in pharmaceutical innovation and public health.


Latest News

Pfizer Inc. Advances Obesity Treatment and Secures Landmark U.S. Government Agreement Under CEO Albert Bourla

Pfizer, led by CEO Albert Bourla, is aggressively expanding in obesity treatments with a $4.9 billion acquisition of Metsera and has reached a landmark agreement with the U.S. government to lower drug costs while boosting U.S.-based manufacturing and research investments. Bourla emphasized the deal's benefit for American patients and Pfizer's stability in tariffs and pricing, citing a $70 billion investment plan in U.S. manufacturing and R&D over coming years.
Source: http://www.pfizer.com/newsroom/press-releases



Disclaimer.
The information provided in this document is for general informational purposes only and is not guaranteed to be complete. While we strive to ensure the accuracy of the content, we cannot guarantee that the details mentioned are up-to-date or applicable to all scenarios. Topics about Pfizer Inc. are subject to change from time to time.

Comments

No comment yet